Specialty Drugs Advance Care for Autoimmune & Inflammatory Diseases
HereS a breakdown of the provided references, formatted for clarity:
- Tremfya Prescribing Details. Johnson & Johnson. Accessed November 19,2025. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf
- Why choose Tremfya? Tremfya. Accessed November 19, 2025. https://www.tremfya.com/crohns-disease/results/
- Feuerstein JD,Ho EY,Shmidt E,et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterol. 2021;160(7):2496-2508. doi:10.1053/j.gastro.2021.04.022
- US FDA approves Tremfya (guselkumab). News release. Johnson & Johnson. March 20, 2025. Accessed November 19, 2025. (Link is incomplete in the provided text, but would likely be to a Johnson & Johnson press release).
Key Observations:
* Tremfya focus: The majority of the references directly relate to the drug Tremfya (guselkumab) and its use in Crohn’s disease.
* Source Variety: The references include a prescribing information document, a website page, a peer-reviewed journal article (clinical practice guidelines), and a press release.
* Access Dates: All references accessed on November 19, 2025.
* Johnson & Johnson: Johnson & Johnson is a frequent source, as the manufacturer of tremfya.